Clinical Trial

The Clinical Trials Department at (MDRF) is led by Dr S. Poongothai, who brings over 33 years of distinguished experience in clinical research. With specialised expertise in the design, conduct, and oversight of global Phase II–IV clinical trials, she has supervised 168 international studies while ensuring the highest standards of ethical conduct, regulatory compliance, and scientific rigour. Dr Poongothai has collaborated with leading multinational pharmaceutical companies—including Novo Nordisk, Novartis, Pfizer, GSK, Boehringer Ingelheim, Takeda, Eli Lilly, Bristol Myers Squibb, Roche, PPD, Bayer, and Sanofi-Aventis—and has served as Study Manager for landmark trials such as SOUL, DREAM, ADVANCE, ORIGIN, and EPI-DREAM. Her extensive training includes advanced GCP certification in Singapore, clinical research training at the University of Alabama, translational research at the CDC in Atlanta, and regulatory training at CMC, Vellore.

As Head of the Department, Dr Poongothai has played a pivotal role in strengthening MDRF’s clinical trial infrastructure by ensuring protocol adherence, regulatory readiness, and operational excellence. She has successfully guided the organisation through audits by EMEA, DCGI, and numerous international sponsors. A respected speaker at national and international conferences, she is widely recognised for her expertise in research ethics, protocol development, informed consent, safety reporting, and participant retention. With over 50 peer-reviewed publications exploring depression, impaired glucose tolerance, diabetes, and its complications, she has made significant academic contributions. Her achievements include the Best Poster Presentation Award for participant retention and the Ahuja Award for her work on depression and diabetes. Her invited lectures at institutions such as Duke University, Sanofi-Aventis, and Novo Nordisk further highlight her leadership in advancing India’s clinical trial landscape, while her record of achieving 100% follow-up across more than 168 trials underscores her exceptional professional commitment.

Dr. S. Poongothai

Activities of the Department

Our department has successfully completed 168 national and international clinical trials, all in full compliance with Good Clinical Practice (GCP) guidelines. With a screen failure rate of less than 5%, we take pride in our meticulous approach to trial conduct, reflecting our strong adherence to protocols and thorough understanding of GCP principles.
Our exceptionally low dropout rate highlights the dedication and commitment of our clinical trial team. We ensure consistent patient follow-up through to the completion of each study, achieving a 100% follow-up rate in over 165 trials. Our staff are extensively trained in effective patient engagement, facilitating smooth trial execution and fostering strong rapport with participants. These strengths have positioned MDRF as a recognized nodal center for several pharmaceutical companies.
The team ensures consistent patient follow-ups until the completion of each study. Staff are trained in effective patient engagement, facilitating smooth trial processes and rapport-building. We have track record of 100% follow-up in more than 165 studies. These strengths have helped MDRF gain recognition as a nodal centre by many pharmaceutical companies.
Our department has undergone over 28 external audits which includes EMA, DCGI and assess GCP compliance and protocol adherence, reinforcing our confidence in maintaining high standards

Key Responsibilities in Clinical Study Execution

AWARD

Certificate of appreciation received from NOVO NORDISK during “Clinical Research Coordinator” meeting held on 14th & 15th December 2025

Interested in collaborations ? 

Scroll to Top

Contact Form